Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach

BJU International

Volumn 120, Issue 2, 2017, Pages 197-203

  Albisinni, Simone ^a   Artigas, Carlos ^a   Aoun, Fouad ^a   Biaou, Ibrahim ^a   Grosman, Julien ^a   Gil, Thierry ^a   Hawaux, Eric ^a   Limani, Ksenija ^a   Otte, Francois Xavier ^a   Peltier, Alexandre ^a   Sideris, Spyridon ^a   Sirtaine, Nicolas ^a   Flamen, Patrick ^a   van Velthoven, Roland ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

PCSM; ProstateCancer; Diagnostics; PSMA; recurrence

Indexed keywords

CHOLINE C 11; GALLIUM 68; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; GALLIUM;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEREOTACTIC RADIOSURGERY; THREE DIMENSIONAL IMAGING; BLOOD; CLINICAL DECISION MAKING; DIAGNOSTIC IMAGING; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

AGED; CLINICAL DECISION-MAKING; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 85007602723     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13739     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30
2. van den Bergh RC, van Casteren NJ, van den Broeck T et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol 2016; 69: 802–20
3. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467–79
4. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 2010; 22: 46–55
5. Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 2014; 52: 725–33
6. van Leeuwen PJ, Stricker P, Hruby G et al. (68)Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 2016; 117: 732–9
7. Maurer T, Gschwend JE, Rauscher I et al. Diagnostic efficacy of (68)Gallium-PSMA-PET compared to conventional imaging in lymph node staging of of 130 consecutive patients with intermediate to high-risk prostate cancer. J Urol 2016; 195: 1436–43
8. Verburg FA, Pfister D, Heidenreich A et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43: 397–403
9. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167–72
10. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927–35
11. Schwenck J, Rempp H, Reischl G et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 2017; 44: 92–101
12. Fendler WP, Schmidt DF, Wenter V et al. 68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer. J Nucl Med 2016; 57: 1720–5
13. Roach M, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol 2006; 65: 965–74
14. Teeter AE, Presti JC, Aronson WJ et al. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. Urology 2013; 82: 53–8
15. Hershman DL, Unger JM, Wright JD et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2016; 2: 453–61
16. Aoun F, Peltier A, van Velthoven R. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Bio Med Res Int 2014; 2014: 501213
17. Aoun F, Kourie HR, Artigas C, Roumeguère T. Next revolution in molecular theranostics: personalized medicine for urologic cancers. Future Oncol 2015; 11: 2205–19
18. Rhee H, Thomas P, Shepherd B et al. Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. J Urol 2016; 196: 1261–7
19. Dewes S, Schiller K, Sauter K et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol 2016; 11: 73
20. Morigi JJ, Stricker PD, van Leeuwen PJ et al. Prospective comparison of 18F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who have rising psa after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185–90
21. Rauscher I, Maurer T, Beer AJ et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med 2016; 57: 1713–9
22. 68 Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1794–800
23. Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197–209
24. 68Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668–74
25. O'Kane DB, Lawrentschuk N, Bolton DM. Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection. Urol Ann 2016; 8: 255–7
26. Queiroz MA, Viana P, Santos A, Bastos D, Etchebehere E, Cerri G. Clinical impact of 68Ga-PSMA PET/CT in a patient with biochemical recurrence of prostate cancer. Clin Nucl Med 2016; 41: e417–9
27. Artigas C, Alexiou J, Garcia C et al. Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 2016; 43: 195–6
28. Pyka T, Okamoto S, Dahlbender M et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114–21
29. Sachpekidis C, Eder M, Kopka K et al. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 1288–99
30. Ceci F, Uprimny C, Nilica B et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015; 42: 1284–94
31. Ross JS, Sheehan CE, Fisher HA et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357–62
32. Shakespeare TP. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiat Oncol 2015; 10: 233
33. Ost P, Bossi A, Decaestecker K et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015; 67: 852–63